| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
UBS analyst Ashwani Verma maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $195 to $220.
Piper Sandler analyst David Amsellem reiterates AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $284 t...
Calico Life Sciences LLC (Calico), a biotechnology organization focused on aging and age-related diseases and founded by Alphab...
Citigroup analyst Geoff Meacham maintains AbbVie (NYSE:ABBV) with a Neutral and lowers the price target from $240 to $235.
JP Morgan analyst Chris Schott maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $250 to $260.
Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap gi...